Product Description: Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder[1][2][3][4].
Applications: Neuroscience-Neuromodulation
Formula: C17H22N4O2
References: [1]Linda S Brady, et al. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discov. 2019 Dec;14(12):1213-1219./[2]Halff EF, et al. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46(1):60-74. /[3]Ågren R, et al. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics. Int J Neuropsychopharmacol. 2023 Sep 25;26(9):599-606. /[4]Yu J, et al. Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery. Clin Transl Med. 2024 Feb;14(2):e1576.
CAS Number: 2133417-13-5
Molecular Weight: 314.38
Compound Purity: 99.92
Research Area: Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: 5-HT Receptor;Dopamine Receptor;Trace Amine-associated Receptor (TAAR)